var data={"title":"Grover's disease (transient and persistent acantholytic dermatosis)","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"topicTitle\">Grover's disease (transient and persistent acantholytic dermatosis)</div><dl id=\"topicContributors\"><dt><span> </span>Authors:</dt><dd><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/contributors\" class=\"contributor contributor_credentials\">Helge Riemann, MD</a></dd><dd><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/contributors\" class=\"contributor contributor_credentials\">Whitney A High, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/contributors\" class=\"contributor contributor_credentials\">Robert P Dellavalle, MD, PhD, MSPH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/contributors\" class=\"contributor contributor_credentials\">Rosamaria Corona, MD, DSc</a></dd></dl><p class=\"disclosureLink\"><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/contributor-disclosure\" class=\"contributor contributor_credentials\">Contributor Disclosures</a></p><div id=\"reviewProcess\"><span>All topics are updated as new evidence becomes available and our <a href=\"https://www.uptodate.com/home/editorial-policy\" target=\"_blank\" class=\"policy policy_editorialpolicy\">peer review process</a> is complete.</span></div><div id=\"literatureReviewDate\"><span class=\"emphasis\">Literature review current through:</span>&#160;Feb 2018.&#160;&#124;&#160;<span class=\"emphasis\">This topic last updated:</span>&#160;Dec 05, 2017.</div><div id=\"topicWhatsNewContainer\"></div><div id=\"topicText\"><p class=\"headingAnchor\" id=\"H1\"><span class=\"h1\">INTRODUCTION</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In 1970, Ralph Grover presented a series of six patients with a pruritic, papular, <span class=\"nowrap\">and/or</span> papulovesicular rash upon the trunk that cleared within weeks [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/1\" class=\"abstract_t\">1</a>]. Histopathologic analysis revealed a characteristic pattern of acantholysis within the epidermis, and Grover named the disease &quot;transient acantholytic dermatosis.&quot; Subsequent reports described an often chronic course, but essentially identical histologic findings, and the term &quot;transient and persistent acantholytic dermatosis&quot; was proposed [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/2,3\" class=\"abstract_t\">2,3</a>]. However, the eponym, &quot;Grover's disease,&quot; remains in wide use.</p><p class=\"headingAnchor\" id=\"H2\"><span class=\"h1\">EPIDEMIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The prevalence and incidence of Grover's disease have not been firmly established. In a study from Switzerland, Grover's disease was diagnosed in just 24 of more than 30,000 skin biopsies [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/4\" class=\"abstract_t\">4</a>].</p><p>It is thought that Grover's disease affects chiefly white adults in the fifth decade or later and appears to be approximately 1.6 to 2.1 times more common in men than in women [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/5,6\" class=\"abstract_t\">5,6</a>]. Grover's disease appears less common in darker-skinned individuals but has been reported [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/5\" class=\"abstract_t\">5</a>].</p><p class=\"headingAnchor\" id=\"H3\"><span class=\"h1\">ETIOLOGY</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The etiology of Grover's disease is unknown. Suspected triggers of disease activity include heat and sweating, sunlight, ionizing irradiation, end-stage renal <span class=\"nowrap\">disease/hemodialysis,</span> mechanical irritation or prolonged bedrest, and solid organ transplantation [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/7-10\" class=\"abstract_t\">7-10</a>].</p><p>Some cases of Grover's disease have been associated with medications, such as sulfadoxine-pyrimethamine, <a href=\"topic.htm?path=ribavirin-drug-information\" class=\"drug drug_general\">ribavirin</a>, <a href=\"topic.htm?path=anastrozole-drug-information\" class=\"drug drug_general\">anastrozole</a>, interleukin-4, <a href=\"topic.htm?path=cetuximab-drug-information\" class=\"drug drug_general\">cetuximab</a>, BRAF inhibitors (eg, <a href=\"topic.htm?path=vemurafenib-drug-information\" class=\"drug drug_general\">vemurafenib</a>, <a href=\"topic.htm?path=dabrafenib-drug-information\" class=\"drug drug_general\">dabrafenib</a>), and immune checkpoint inhibitors (eg, <a href=\"topic.htm?path=ipilimumab-drug-information\" class=\"drug drug_general\">ipilimumab</a>) [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/1,11-22\" class=\"abstract_t\">1,11-22</a>]. (See <a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy#H3204039\" class=\"medical medical_review\">&quot;Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy&quot;, section on 'Vemurafenib and dabrafenib'</a>.)</p><p>One series of 300 patients with Grover's disease reported an association with other coexisting dermatoses including atopic dermatitis, contact dermatitis, and xerosis cutis [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/5\" class=\"abstract_t\">5</a>]. Finally, smaller series and case reports have detailed an association with pyoderma gangrenosum, bacterial and viral infections, and occasionally malignancies were described [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/5,10,23,24\" class=\"abstract_t\">5,10,23,24</a>].</p><p>Although Grover's disease may show histologic similarities to Darier disease, it does not appear to be caused by the same mutations in the <em>ATP2A2</em> gene [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/25\" class=\"abstract_t\">25</a>]. (See <a href=\"topic.htm?path=darier-disease#H7872132\" class=\"medical medical_review\">&quot;Darier disease&quot;, section on 'Pathogenesis'</a>.)</p><p>Grover's disease is frequently seen in association with increased sweating, whether caused by heat or bedrest. Some investigators believe the condition may be precipitated by occlusion of eccrine sweat glands, a process that may lead to miliaria as well. In support of this hypothesis, one study used electron microscopy to identify occlusion of the acrosyringia in three patients whose disease had definitive temporal relationship to increased perspiration [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/26\" class=\"abstract_t\">26</a>]. However, in a conflicting study, occlusion of eccrine duct was noted in just 2 of 11 cases [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/27\" class=\"abstract_t\">27</a>]. It is unclear if this disparity can be attributed to differences in methodology or patient selection.</p><p>In contrast with an association with sweating, a review of biopsies read at a dermatopathology center in New York City found that Grover's disease was diagnosed four times more often in the winter months than in the summer [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/6\" class=\"abstract_t\">6</a>]. The authors suggested that Grover's disease might be promoted when xerotic skin is exposed to cold, dry air.</p><p class=\"headingAnchor\" id=\"H4\"><span class=\"h1\">CLINICAL FEATURES</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>In most cases, Grover's disease affects the trunk, especially the central area of chest and back (<a href=\"image.htm?imageKey=DERM%2F106706\" class=\"graphic graphic_picture graphicRef106706 \">picture 1</a>). Typically, the eruption consists of intensely pruritic, erythematous papules (<a href=\"image.htm?imageKey=PC%2F76504\" class=\"graphic graphic_picture graphicRef76504 \">picture 2</a>). Truncal prominence is a common feature, although the limbs (particularly the proximal limbs) may be affected as well. Involvement of the face, palms, or soles is unlikely to occur [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/5\" class=\"abstract_t\">5</a>]. Extensive disease or atypical presentations are more common in patients with a history of malignancy, recent chemotherapy, or recent transplant [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/28\" class=\"abstract_t\">28</a>].</p><p>Often, the disease is first noticed after a period of fever or after a hospitalization with prolonged bedrest. This has prompted speculation about an etiology involving sweating or dysfunction of sweat ducts [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/26\" class=\"abstract_t\">26</a>].</p><p>Keratotic papules, papulovesicles, vesicles, and papulosquamous plaques reminiscent of psoriasis or parapsoriasis have also been described [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/5\" class=\"abstract_t\">5</a>]. The lesions of Grover's disease are frequently eroded and crusted.</p><p>As would be expected, given the name &quot;transient and persistent acantholytic dermatosis,&quot; the temporal course of the disease is highly variable. Patients may present with a self-limited eruption, a waxing and waning course, or a persistent, recalcitrant pattern. In Colorado, a semiarid environment, it is not uncommon to see a flare in disease activity during the drier winter months.</p><p>Although Grover's disease is a benign condition, the associated pruritus may be severe and can have a significant impact quality of life.</p><p class=\"headingAnchor\" id=\"H5\"><span class=\"h1\">DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>The diagnosis of Grover's disease is typically made on skin biopsy in the appropriate clinical setting. The key histopathologic feature of Grover's disease is acantholysis (<a href=\"image.htm?imageKey=PC%2F56584\" class=\"graphic graphic_picture graphicRef56584 \">picture 3</a>)&nbsp;[<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/23,29\" class=\"abstract_t\">23,29</a>]; acantholysis is the dissociation of keratinocytes from one another in the epidermis.</p><p>A number of histologic subtypes have been identified [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/29,30\" class=\"abstract_t\">29,30</a>]. Different histologic subtypes may be observed within a single biopsy specimen.</p><p class=\"headingAnchor\" id=\"H6\"><span class=\"h1\">DIFFERENTIAL DIAGNOSIS</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>Grover&rsquo;s disease should be differentiated from other skin disorders histologically characterized by acantholysis. These include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Darier disease</strong> &ndash; Darier disease is a genodermatosis caused by mutations in the keratinocyte calcium transporter gene <em>ATP2A2</em>. It may demonstrate clinical and histologic similarities to Grover's disease. Unlike Grover's disease, Darier disease usually presents first during puberty, favors intertriginous areas, and is associated with concomitant nail changes, palmar pits, and mucosal manifestations (<a href=\"image.htm?imageKey=DERM%2F56168%7EDERM%2F70000%7EDERM%2F86184\" class=\"graphic graphic_picture graphicRef56168 graphicRef70000 graphicRef86184 \">picture 4A-C</a>). Darier disease is inherited in autosomal dominant fashion, and a family history of similar illness may suggest Darier disease rather than Grover's disease. (See <a href=\"topic.htm?path=darier-disease\" class=\"medical medical_review\">&quot;Darier disease&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Hailey-Hailey disease </strong>&ndash; Hailey-Hailey disease is also an autosomal dominant condition. It is caused by a mutation in the <em>ATP2C1</em> gene that encodes for a membrane-bound transporter protein present on keratinocytes. Hailey-Hailey disease is characterized by recurrent blisters and crusted, vegetating erosions in intertriginous areas (<a href=\"image.htm?imageKey=DERM%2F61689%7EDERM%2F74552%7EDERM%2F76004\" class=\"graphic graphic_picture graphicRef61689 graphicRef74552 graphicRef76004 \">picture 5A-C</a>). As with Darier disease, a positive family history suggests this inherited disorder rather than Grover's disease. (See <a href=\"topic.htm?path=hailey-hailey-disease-benign-familial-pemphigus\" class=\"medical medical_review\">&quot;Hailey-Hailey disease (benign familial pemphigus)&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Pemphigus</strong> &ndash; Pemphigus is an autoimmune bullous disorder that may be distinguished from Grover's disease by positive direct immunofluorescence studies performed on involved skin (<a href=\"image.htm?imageKey=DERM%2F82837%7EDERM%2F82838\" class=\"graphic graphic_picture graphicRef82837 graphicRef82838 \">picture 6A-B</a>). (See <a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">&quot;Pathogenesis, clinical manifestations, and diagnosis of pemphigus&quot;</a>.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><strong>Galli-Galli disease</strong> &ndash; Galli-Galli disease, the acantholytic variant of Dowling-Degos disease, is characterized by reticulated hyperpigmentation of major flexures and intertriginous areas [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/31\" class=\"abstract_t\">31</a>].</p><p/><p class=\"headingAnchor\" id=\"H7\"><span class=\"h1\">TREATMENT</span><span class=\"headingEndMark\">&#160;&#8212;&#160;</span>There are no published randomized clinical trials of therapies for Grover's disease. Nearly all evidence for therapies comes from case series, case reports, and clinical experience.</p><p>Since heat and sweating may be triggers for Grover's disease, patients should be advised to avoid activities that expose them to such triggers whenever possible [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/5,11,13\" class=\"abstract_t\">5,11,13</a>].</p><p>High-potency topical corticosteroids (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>), moisturizers, and emollients are typically recommended as first-line therapy [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/3-5\" class=\"abstract_t\">3-5</a>]. Limited data suggest that topical corticosteroids improve the condition in approximately 50 percent of cases [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/4\" class=\"abstract_t\">4</a>]. Antihistamines may be helpful for symptomatic relief of itching [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/3\" class=\"abstract_t\">3</a>]. Many dermatologists believe sedating antihistamines, if tolerated, possess superior antipruritic activity, although the evidence supporting this is limited. (See <a href=\"topic.htm?path=pruritus-overview-of-management#H8354417\" class=\"medical medical_review\">&quot;Pruritus: Overview of management&quot;, section on 'Antihistamines'</a>.)</p><p>Additional treatment options described in the literature include:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic corticosteroids&nbsp;[<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/32\" class=\"abstract_t\">32</a>]. Relapse appears to be common upon withdrawal.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Topical vitamin D analogs [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/33-35\" class=\"abstract_t\">33-35</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic retinoids [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/36,37\" class=\"abstract_t\">36,37</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Phototherapy and photochemotherapy (PUVA) [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/38,39\" class=\"abstract_t\">38,39</a>]. PUVA may cause an initial exacerbation of symptoms before producing benefit.</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Red-light 5-aminolevulinic acid photodynamic therapy (ALA-PDT) [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/40\" class=\"abstract_t\">40</a>].</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span><a href=\"topic.htm?path=etanercept-including-biosimilars-of-etanercept-drug-information\" class=\"drug drug_general\">Etanercept</a> has been described as an effective treatment for refractory Grover&rsquo;s disease in a case report [<a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/41\" class=\"abstract_t\">41</a>].</p><p/><p>In the absence of stronger evidence for therapies, we suggest a sequential approach starting with safer, cheaper, and more readily available therapies. Patients who fail such therapies can then undergo trials of other therapies. Such a strategy is presented below.</p><p>First line:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Avoidance of triggering factors (eg, heat, sweating)</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Moisturizers, emollients</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Topical corticosteroids (high-potency fluorinated compounds) (<a href=\"image.htm?imageKey=DERM%2F62402\" class=\"graphic graphic_table graphicRef62402 \">table 1</a>)</p><p/><p>Second line:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Topical vitamin D-analogs (calcipotriene 0.005% twice daily); treat for three to four weeks before assessing clinical response</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Oral antihistamines</p><p/><p>Third line:</p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic corticosteroids (eg, <a href=\"topic.htm?path=prednisone-drug-information\" class=\"drug drug_general\">prednisone</a> starting at 20 to 40 mg daily and tapering over two to three weeks)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Systemic retinoids (<a href=\"topic.htm?path=isotretinoin-drug-information\" class=\"drug drug_general\">isotretinoin</a> 40 mg daily for 2 to 12 weeks; taper to as little as 10 mg daily for prolonged control)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>PUVA; may initially exacerbate disease before producing benefit</p><p/><p class=\"headingAnchor\" id=\"H8\"><span class=\"h1\">SUMMARY AND RECOMMENDATIONS</span></p><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>Grover's disease (transient and persistent acantholytic dermatosis) is an uncommon pruritic, papular, <span class=\"nowrap\">and/or</span> papulovesicular rash that most commonly affects the trunk (<a href=\"image.htm?imageKey=PC%2F76504\" class=\"graphic graphic_picture graphicRef76504 \">picture 2</a>). The etiology is unknown, but there appears to be an association with heat and sweating. (See <a href=\"#H3\" class=\"local\">'Etiology'</a> above and <a href=\"#H4\" class=\"local\">'Clinical features'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>The diagnosis of Grover's disease is typically made on skin biopsy in the appropriate clinical setting. (See <a href=\"#H5\" class=\"local\">'Diagnosis'</a> above.)</p><p/><p class=\"bulletIndent1\"><span class=\"glyph\">&#9679;</span>There are no published randomized clinical trials of therapies for Grover's disease. In the absence of stronger evidence for treatment, we suggest a sequential approach starting with safer, cheaper, and more readily available therapies, which include high-potency topical corticosteroids and emollients (<a href=\"grade.htm?i=6\" class=\"grade\">Grade 2C</a>). Patients who fail such therapies can then undergo trials of other therapies. (See <a href=\"#H7\" class=\"local\">'Treatment'</a> above.)</p></div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\"><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/1\" class=\"nounderline abstract_t\">Grover RW. Transient acantholytic dermatosis. Arch Dermatol 1970; 101:426.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/2\" class=\"nounderline abstract_t\">Simon RS, Bloom D, Ackerman AB. Persistent acantholytic dermatosis. A variant of transient acantholytic dermatosis (Grover disease). Arch Dermatol 1976; 112:1429.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/3\" class=\"nounderline abstract_t\">Heenan PJ, Quirk CJ. Transient acantholytic dermatosis. Br J Dermatol 1980; 102:515.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/4\" class=\"nounderline abstract_t\">Streit M, Paredes BE, Braathen LR, Brand CU. [Transitory acantholytic dermatosis (Grover disease). An analysis of the clinical spectrum based on 21 histologically assessed cases]. Hautarzt 2000; 51:244.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/5\" class=\"nounderline abstract_t\">Parsons JM. Transient acantholytic dermatosis (Grover's disease): a global perspective. J Am Acad Dermatol 1996; 35:653.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/6\" class=\"nounderline abstract_t\">Scheinfeld N, Mones J. Seasonal variation of transient acantholytic dyskeratosis (Grover's disease). J Am Acad Dermatol 2006; 55:263.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/7\" class=\"nounderline abstract_t\">Quirk CJ, Heenan PJ. Grover's disease: 34 years on. Australas J Dermatol 2004; 45:83.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/8\" class=\"nounderline abstract_t\">Boutli F, Voyatzi M, Lefaki I, et al. Transient acantholytic dermatosis (Grover's disease) in a renal transplant patient. J Dermatol 2006; 33:178.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/9\" class=\"nounderline abstract_t\">Ippoliti G, Paulli M, Lucioni M, et al. Grover's Disease after Heart Transplantation: A Case Report. Case Rep Transplant 2012; 2012:126592.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/10\" class=\"nounderline abstract_t\">Zhu HJ, Clark LN, Deloney LA, McDonald JE. Grover disease (transient acantholytic dermatosis) in acute myeloid leukemia on FDG PET/CT. Clin Nucl Med 2014; 39:e173.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/11\" class=\"nounderline abstract_t\">Hu CH, Michel B, Farber EM. Transient acantholytic dermatosis (Grover's disease). A skin disorder related to heat and sweating. Arch Dermatol 1985; 121:1439.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/12\" class=\"nounderline abstract_t\">Casanova JM, Pujol RM, Taberner R, et al. Grover's disease in patients with chronic renal failure receiving hemodialysis: clinicopathologic review of 4 cases. J Am Acad Dermatol 1999; 41:1029.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/13\" class=\"nounderline abstract_t\">French LE, Piletta PA, Etienne A, et al. Incidence of transient acantholytic dermatosis (Grover's disease) in a hospital setting. Dermatology 1999; 198:410.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/14\" class=\"nounderline abstract_t\">Ott, A. Persistent acantholytic dermatosis in a patient with increased sensitivity to light. Zeitschrift fuer Hautkrankheiten 1993; 62:369.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/15\" class=\"nounderline abstract_t\">Antunes I, Azevedo F, Mesquita-Guimar&atilde;es J, et al. Grover's disease secondary to ribavirin. Br J Dermatol 2000; 142:1257.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/16\" class=\"nounderline abstract_t\">Mahler SJ, De Villez RL, Pulitzer DR. Transient acantholytic dermatosis induced by recombinant human interleukin 4. J Am Acad Dermatol 1993; 29:206.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/17\" class=\"nounderline abstract_t\">Tscharner GG, B&uuml;hler S, Borner M, Hunziker T. Grover's disease induced by cetuximab. Dermatology 2006; 213:37.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/18\" class=\"nounderline abstract_t\">Carlos G, Anforth R, Clements A, et al. Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma. JAMA Dermatol 2015; 151:1103.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/19\" class=\"nounderline abstract_t\">Anforth R, Fernandez-Pe&ntilde;as P, Long GV. Cutaneous toxicities of RAF inhibitors. Lancet Oncol 2013; 14:e11.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/20\" class=\"nounderline abstract_t\">Crockett JS, Burkemper NM. Grover disease (transient acantholytic dermatosis) induced by anastrozole. Cutis 2011; 88:175.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/21\" class=\"nounderline abstract_t\">Munoz J, Guillot B, Girard C, et al. First report of ipilimumab-induced Grover disease. Br J Dermatol 2014; 171:1236.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/22\" class=\"nounderline abstract_t\">Kaunitz GJ, Loss M, Rizvi H, et al. Cutaneous Eruptions in Patients Receiving Immune Checkpoint Blockade: Clinicopathologic Analysis of the Nonlichenoid Histologic Pattern. Am J Surg Pathol 2017; 41:1381.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/23\" class=\"nounderline abstract_t\">Guana AL, Cohen PR. Transient acantholytic dermatosis in oncology patients. J Clin Oncol 1994; 12:1703.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/24\" class=\"nounderline abstract_t\">Andersen BL. Pyoderma gangrenosum associated with transient acantholytic dermatosis (pemphigus erythematosus-like) and paraproteinemia. Acta Derm Venereol 1981; 61:77.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/25\" class=\"nounderline abstract_t\">Powell J, Sakuntabhai A, James M, et al. Grover's disease, despite histological similarity to Darier's disease, does not share an abnormality in the ATP2A2 gene. Br J Dermatol 2000; 143:658.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/26\" class=\"nounderline abstract_t\">Hashimoto K, Moiin A, Chang MW, Tada J. Sudoriferous acrosyringeal acantholytic disease. A subset of Grover's disease. J Cutan Pathol 1996; 23:151.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/27\" class=\"nounderline abstract_t\">Antley CM, Carrington PR, Mrak RE, Smoller BR. Grover's disease (transient acantholytic dermatosis): relationship of acantholysis to acrosyringia. J Cutan Pathol 1998; 25:545.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/28\" class=\"nounderline abstract_t\">Gantz M, Butler D, Goldberg M, et al. Atypical features and systemic associations in extensive cases of Grover disease: A systematic review. J Am Acad Dermatol 2017; 77:952.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/29\" class=\"nounderline abstract_t\">Davis MD, Dinneen AM, Landa N, Gibson LE. Grover's disease: clinicopathologic review of 72 cases. Mayo Clin Proc 1999; 74:229.</a></li><li class=\"breakAll\">Weedon D. Skin Pathology, Churchill Livingstone, London 2002. p.297.</li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/31\" class=\"nounderline abstract_t\">Gilchrist H, Jackson S, Morse L, et al. Galli-Galli disease: A case report with review of the literature. J Am Acad Dermatol 2008; 58:299.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/32\" class=\"nounderline abstract_t\">Er&ouml;s N, Kov&aacute;cs A, K&aacute;rolyi Z. Successful treatment of transient acantholytic dermatosis with systemic steroids. J Dermatol 1998; 25:469.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/33\" class=\"nounderline abstract_t\">Keohane SG, Cork MJ. Treatment of Grover's disease with calcipotriol (Dovonex). Br J Dermatol 1995; 132:832.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/34\" class=\"nounderline abstract_t\">Mota AV, Correia TM, Lopes JM, Guimar&atilde;es JM. Successful treatment of Grover's disease with calcipotriol. Eur J Dermatol 1998; 8:33.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/35\" class=\"nounderline abstract_t\">Hayashi H, Yokota K, Koizumi H, Shimizu H. Treatment of Grover's disease with tacalcitol. Clin Exp Dermatol 2002; 27:160.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/36\" class=\"nounderline abstract_t\">Dodd HJ, Sarkany I. Persistent acantholytic dermatosis. Clin Exp Dermatol 1984; 9:431.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/37\" class=\"nounderline abstract_t\">Helfman RJ. Grover's disease treated with isotretinoin. Report of four cases. J Am Acad Dermatol 1985; 12:981.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/38\" class=\"nounderline abstract_t\">Breuckmann F, Appelhans C, Altmeyer P, Kreuter A. Medium-dose ultraviolet A1 phototherapy in transient acantholytic dermatosis (Grover's disease). J Am Acad Dermatol 2005; 52:169.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/39\" class=\"nounderline abstract_t\">Paul BS, Arndt KA. Response of transient acantholytic dermatosis to photochemotherapy. Arch Dermatol 1984; 120:121.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/40\" class=\"nounderline abstract_t\">Liu S, Letada PR. Successful novel treatment of recalcitrant transient acantholytic dermatosis (Grover disease) using red light 5-aminolevulinic acid photodynamic therapy. Dermatol Surg 2013; 39:960.</a></li><li><a href=\"https://www.uptodate.com/contents/grovers-disease-transient-and-persistent-acantholytic-dermatosis/abstract/41\" class=\"nounderline abstract_t\">Norman R, Chau V. Use of etanercept in treating pruritus and preventing new lesions in Grover disease. J Am Acad Dermatol 2011; 64:796.</a></li></ol></div><div id=\"topicVersionRevision\">Topic 5566 Version 10.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul id=\"innerOutline\"><li class=\"sr-button\"><a href=\"#H8\"><span>SUMMARY &amp; RECOMMENDATIONS</span></a></li><li><a href=\"#H1\" id=\"outline-link-H1\">INTRODUCTION</a></li><li><a href=\"#H2\" id=\"outline-link-H2\">EPIDEMIOLOGY</a></li><li><a href=\"#H3\" id=\"outline-link-H3\">ETIOLOGY</a></li><li><a href=\"#H4\" id=\"outline-link-H4\">CLINICAL FEATURES</a></li><li><a href=\"#H5\" id=\"outline-link-H5\">DIAGNOSIS</a></li><li><a href=\"#H6\" id=\"outline-link-H6\">DIFFERENTIAL DIAGNOSIS</a></li><li><a href=\"#H7\" id=\"outline-link-H7\">TREATMENT</a></li><li><a href=\"#H8\" id=\"outline-link-H8\">SUMMARY AND RECOMMENDATIONS</a></li><li><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DERM/5566|PIC\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"PICTURES\">PICTURES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/106706\" class=\"graphic graphic_picture\">- Grover disease chest</a></li><li><a href=\"image.htm?imageKey=PC/76504\" class=\"graphic graphic_picture\">- Grover's disease</a></li><li><a href=\"image.htm?imageKey=PC/56584\" class=\"graphic graphic_picture\">- Grover's histology</a></li><li><a href=\"image.htm?imageKey=DERM/56168\" class=\"graphic graphic_picture\">- Darier disease - light skin</a></li><li><a href=\"image.htm?imageKey=DERM/70000\" class=\"graphic graphic_picture\">- Darier disease - dark skin</a></li><li><a href=\"image.htm?imageKey=DERM/86184\" class=\"graphic graphic_picture\">- Darier mucosal</a></li><li><a href=\"image.htm?imageKey=DERM/61689\" class=\"graphic graphic_picture\">- Hailey-Hailey 1</a></li><li><a href=\"image.htm?imageKey=DERM/74552\" class=\"graphic graphic_picture\">- Hailey-Hailey 2</a></li><li><a href=\"image.htm?imageKey=DERM/76004\" class=\"graphic graphic_picture\">- Hailey-Hailey 3</a></li><li><a href=\"image.htm?imageKey=DERM/82837\" class=\"graphic graphic_picture\">- Pemphigus vulgaris DIF</a></li><li><a href=\"image.htm?imageKey=DERM/82838\" class=\"graphic graphic_picture\">- Pemphigus foliaceus DIF</a></li></ul></li><li><div id=\"DERM/5566|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DERM/62402\" class=\"graphic graphic_table\">- Topical corticosteroids</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li class=\"plainItem\"><a href=\"topic.htm?path=cutaneous-side-effects-of-molecularly-targeted-therapy-and-other-biologic-agents-used-for-cancer-therapy\" class=\"medical medical_review\">Cutaneous side effects of molecularly targeted therapy and other biologic agents used for cancer therapy</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=darier-disease\" class=\"medical medical_review\">Darier disease</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=hailey-hailey-disease-benign-familial-pemphigus\" class=\"medical medical_review\">Hailey-Hailey disease (benign familial pemphigus)</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pathogenesis-clinical-manifestations-and-diagnosis-of-pemphigus\" class=\"medical medical_review\">Pathogenesis, clinical manifestations, and diagnosis of pemphigus</a></li><li class=\"plainItem\"><a href=\"topic.htm?path=pruritus-overview-of-management\" class=\"medical medical_review\">Pruritus: Overview of management</a></li></ul></div></div>","javascript":null}